Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05783791 · ClinicalTrials.gov registry record
Development of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi Syndrome
A clinical trial, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- 11
- Enrollment target
NCT05783791: Completed study, sponsored by University of Wisconsin, Madison.
NCT05783791 is a clinical trial that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05783791 has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- 11 participants
- Enrollment target
Study Summary
The overall purpose of this project is to establish the capability of screening for Angelman syndrome (AS) and Prader-Willi syndrome (PWS) in public health newborn screening (NBS) programs, with an aim of developing and validating a screening test for AS and PWS.
Interventions
- DIAGNOSTIC_TEST Newborn Screening Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2023-04-20 |
| Est. Completion | 2023-07-21 |
What the finished NCT05783791 record still lists
NCT05783791 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 11 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Newborn Screening Assay is the first listed.
NCT05783791 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05783791 about?
NCT05783791 is a clinical study titled "Development of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi Syndrome". The overall purpose of this project is to establish the capability of screening for Angelman syndrome (AS) and Prader-Willi syndrome (PWS) in public health newborn screening (NBS) programs, with an aim of developing and validating a screening test for AS and PWS.
What is the current status of trial NCT05783791?
This trial is currently completed. The enrollment target is 11 participants. The study started on 2023-04-20. Estimated completion is 2023-07-21.
What interventions are being tested in trial NCT05783791?
The interventions under investigation include: Newborn Screening Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05783791?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI